Jun 11, 2014Boston Scientific Announces One-Year Results In The VANTAGE Clinical Study Evaluating The Vercise™ DBS SystemData Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease
Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent...
Jun 10, 2014Clinical Study Results Demonstrate Therapeutic Advantages Of The Boston Scientific Vercise™ DBS System For Patients With Parkinson's DiseaseData Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...
Jun 4, 2014Boston Scientific Initiates the RESPOND Post Market Registry Evaluating Clinical Outcomes in Patients Implanted With Lotus™ Valve System
Boston Scientific Corporation (NYSE: BSX) has initiated the RESPOND Post Market Registry to assess real world performance of the Lotus™ Valve System. The RESPOND Registry will collect data on...
May 21, 2014EVOLVE Study Data Presented Today at EuroPCR 2014 Also Demonstrate Excellent Safety Profile
Boston Scientific Corporation (NYSE: BSX) reported positive three-year follow-up data for the EVOLVE clinical trial, comparing the safety and performance of the SYNERGY™ Everolimus-Eluting...
May 21, 2014Boston Scientific Lotus™ Valve System demonstrates strong performance and safety profile at six months
Only 1.1 Percent of Patients Experienced Moderate Paravalvular Aortic Regurgitation; No Severe Cases Occurred Further validating its advanced transcatheter aortic valve implantation (TAVI)...